482 reports of this reaction
2.3% of all FEBUXOSTAT TABLETS 80 MG reports
#4 most reported adverse reaction
ANAEMIA is the #4 most commonly reported adverse reaction for FEBUXOSTAT TABLETS 80 MG, manufactured by Macleods Pharmaceuticals Limited. There are 482 FDA adverse event reports linking FEBUXOSTAT TABLETS 80 MG to ANAEMIA. This represents approximately 2.3% of all 21,060 adverse event reports for this drug.
Patients taking FEBUXOSTAT TABLETS 80 MG who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is a less commonly reported adverse event for FEBUXOSTAT TABLETS 80 MG, but still significant enough to appear in the safety profile.
In addition to anaemia, the following adverse reactions have been reported for FEBUXOSTAT TABLETS 80 MG:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 482 FDA reports for FEBUXOSTAT TABLETS 80 MG. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 2.3% of all adverse event reports for FEBUXOSTAT TABLETS 80 MG, making it a notable side effect.
If you experience anaemia while taking FEBUXOSTAT TABLETS 80 MG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.